Greenland Mines (NASDAQ: GRML) announced on Tuesday that its board of directors has adopted a one-year stockholder rights plan, effective July 22, 2026, aimed at protecting stockholders from coercive takeover tactics and ensuring they receive full and fair value in any acquisition proposal.

The plan will remain in effect for one year unless it is redeemed, exchanged, or terminated earlier. It is designed to give the board sufficient time to evaluate any acquisition proposals and to prevent any single entity from gaining control of the company without offering a fair price to all stockholders.

Under the terms of the plan, the rights generally become exercisable if a person or group acquires beneficial ownership of 15% or more of the company's outstanding common shares. Certain existing holders are grandfathered under specified conditions, according to the company's press release.

Greenland Mines emphasized that the plan does not prevent the board from considering or accepting offers that it determines to be in the best interests of stockholders.

A rights plan, commonly referred to as a "poison pill," is a defensive mechanism used by companies to deter hostile takeovers by making it prohibitively expensive for an acquirer to accumulate a controlling stake without negotiating with the board. The 15% trigger threshold aligns with the lower end of the typical 10–20% range commonly seen in such plans. The limited one-year duration indicates the board may be responding to specific takeover interest or prevailing market conditions while still keeping the door open for a fair transaction.

Greenland Mines operates two divisions: Mining and Biotech. The mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to the closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. Nd-Pr are the primary rare earth inputs for high-performance permanent magnets used in electric vehicle motors, wind turbines, and defense systems. Western governments have identified rare earth supply chain diversification as a strategic priority, as China currently dominates global rare earth processing and refining capacity. The biotech division includes Klotho's KLTO-202, whose primary indication is ALS, a progressive neurodegenerative disease with limited approved treatment options.

The company's broader strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. This includes advancing its North Atlantic Critical Metals Corridor vision, which seeks to connect Greenland-based resources with allied downstream jurisdictions and industrial infrastructure.

Rights plan adoptions have historically drawn scrutiny from institutional investors and proxy advisory firms concerned about entrenchment, though one-year sunset provisions are generally viewed as more shareholder-friendly than longer-duration plans.

Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The company undertakes no duty to update this information unless required by law.